Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

<ul><li>Russia has signed up with four large manufacturers in India to produce 300 million doses of the <keyword id="9739267" type="UNKNOWN" weightage="20" keywordseo="Sputnik-V">Sputnik V</keyword> vaccine in 2021.</li><li>This triples the amount of the vaccine that Russia has initially contracted to be manufactured in India. </li><li>According to the Russian Embassy, the first samples of the COVID-19 vaccine produced in India are already being tested by the Russian Direct Investment Fund (RDIF).</li></ul>Russia has signed on four large manufacturers to produce a whopping 300 million doses of the Sputnik V COVID-19 vaccine in India. This is a three-fold increase in the manufacturing of Sputnik V doses from before. "In India, we have agreements with four large manufacturers. ... India will produce about 300 mln doses or more of the vaccine for us next year," said Russian Direct Investment Fund (RDIF) chief <a href="https://tass.com/world/1236777/amp">Kirill Dmitriev</a>. One of the manufacturers is Hetero Biopharma, which <a href="https://www.livemint.com/news/india/hetero-drugs-to-produce-over-100-million-doses-year-of-sputnik-v-vaccine-11606459369285.html">announced</a> its deal with the RDIF to make more than 100 million doses of the vaccine in November, earlier this year. Dmitriev did not disclose who the three new vendors are. It’s possible that Dr. Reddy’s Laboratories may be roped in since it is already conducting the clinical trials of Sputnik V in India and will also distribute doses, once approval comes in from the DCGA. So far, only three COVID-19 vaccines from Oxford-AstraZeneca, Pfizer-BioNTech and homegrown pharmaceutical company Bharat Biotech, have sought approval for emergency use in the coming weeks. Sputnik V may not be in the running but according to the <a href="https://twitter.com/RusEmbIndia/status/1339813294647902208">Russian Embassy</a>, testing of the first samples of the vaccine that were produced in India is already underway. In trials done outside the country, the Russian vaccine has been found to be more than 91% effective. Like Oxford-AstraZeneca, Stupink V can survive at refrigerated temperatures of between two to five degrees Celsius, which gives it an edge over its competitors. SEE ALSO: <a href="https://www.businessinsider.in/science/news/fda-says-it-will-rapidly-work-toward-authorizing-modernas-covid-19-vaccine/articleshow/79789544.cms" data-type="tilCustomLink">FDA says it will 'rapidly work toward' authorizing Moderna's COVID-19 vaccine</a> <a href="https://www.businessinsider.in/tech/news/facebook-and-google-have-been-accused-of-striking-a-secret-illegal-advertising-deal/articleshow/79778780.cms" data-type="tilCustomLink">Facebook and Google have been accused of striking a secret, illegal advertising deal</a>

India will produce 300 million doses of the Russian Sputnik V COVID-19 vaccine next year

<ul><li>India may receive the first batch of Russia’s <keyword id="9739267" type="UNKNOWN" weightage="20" keywordseo="Sputnik-V">Sputnik V</keyword> COVID-19 vaccine is time for it to open up vaccinations for everyone above the age of 18 years.</li><li>The head of the <keyword id="1397612" type="COMPANY" weightage="20" keywordseo="Russian-Direct-Investment-Fund">Russian Direct Investment Fund</keyword> (RDIF) told Reuters that the vaccine will reach India by May 1.</li><li>The company plans to manufacture 850 million doses of Sputnik V annually in India, but a lot of that will depend on the momentum of technology transfer.</li></ul>India will receive the first batch of Russia’s Sputnik V COVID-19 vaccine by May 1. This is just in time for the country to open up vaccinations for everyone above the age of 18 years. “The first doses will be delivered on May 1,” the head of the Russian Direct Investment Fund (RDIF), Kirill Dmitriev, told <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/india-receive-first-batch-russias-covid-19-vaccine-may-1-interfax-2021-04-26/">Reuters</a>. However, he did not disclose the number of doses that will be a part of the first batch or where they will be manufactured. Sputnik V, developed by Moscow’s Gamaleya National Research Institute of Epidemiology and Microbiology, is the third vaccine after the Serum Institute of India’s (SII) Covishield and Bharat Biotech’s Covaxin to get approval from the Drug Controller General of India (DCGI). <div type="ExtQuote" text="“Following approval in India, it [Sputnik V] will be approved for use in 60 countries with a total population of over 3 billion people.”" auname="Kirill Dmitriev, head of the Russian Direct Investment Fund (RDIF) told reporters on April 14 after Sputnik V got the Drug Controller General of India’s (DCGI) approval"></div> RDIF is in charge of marketing the Sputnik V vaccine globally and has already signed agreements with six leading Indian manufacturers — Hetero Biopharma, Gland Pharma, Stelis Biopharma, Panacea Biotech, Virchow Biotech, and Shilpa Medicare. In this collaboration, RDIF hopes to manufacture over 850 million doses of the vaccine annually. By summer, it plans to hit 50 million doses a month and continue increasing output from there. A lot of this will depend on the momentum of technology transfer to allow Indian manufacturers to produce the vaccine. Virchow Biotech, for instance, is expected to complete its technology transfer between April to June, according to RDIF. Only then will it be able to commence full-scale commercial production of Sputnik V. The vaccine has also been approved by many of India’s neighbours including Sri Lanka, Myanmar and Pakistan. Russia is also lending a helping hand when it comes to Remdesivir. Pharmasyntez, a Russian company, announced that it is ready to ship up to 1 million packs of Remdesivir by the end of May, once it receives the prerequisite approval from the Russian government. <div type="Article" hostid="261" msid="82210121" title="Inside the treacherous black market for Remdesivir in India— from private hospitals to distributors" mstype="2" mssubtype="0"></div> In India, the stocks of Remdesivir have been in short supply as demand for the anti-viral drug increased alongside the surge in cases. This is despite the fact that the <keyword id="6356311" type="COMPANY" weightage="20" keywordseo="World-Health-Organisation">World Health Organisation</keyword> (WHO) has reiterated that there is no conclusive evidence to support the fact that Remdesivir is effective in the treatment of COVID-19. SEE ALSO: <a href="https://www.businessinsider.in/science/health/news/the-pace-of-infections-and-test-positivity-in-maharashtra-is-slowing-down-but-it-is-too-soon-to-celebrate/articleshow/82256149.cms">The pace of infections and test positivity in Maharashtra is slowing down — but it is too soon to celebrate</a> <a href="https://www.businessinsider.in/india/news/india-covid-19-first-wave-versus-second-wave/articleshow/82216963.cms">'We're in a much better situation' claims India's Principal Scientific Advisor as COVID-19 claims more lives than ever before</a>

India will receive the first batch of Sputnik V COVID-19 vaccine by May 1 — in time for the third phase of its vaccination drive

<ul><li>Russia is likely to sell 100 million doses of its COVID-19 vaccine — Sputnik-V — to Indian pharmaceutical Dr Reddy’s Laboratories</li><li>According to the Russian Direct Investment Fund, the deliveries can begin in the late 2020.</li><li>Sputnik V is under Phase III trials in Russia. Gamaleya Research Institute — a part of Russia’s Health Ministry — is testing the vaccine on over 40,000 people.</li></ul>Russia is likely to sell 100 million doses of its COVID-19 vaccine — Sputnik-V — to Indian pharmaceutical Dr Reddy’s Laboratories as soon as it receives regulatory approval in India,<a href="https://in.reuters.com/article/health-coronavirus-russia-reddys/russia-to-sell-covid-19-vaccine-to-indias-dr-reddys-laboratories-idINKBN2671DY?il=0"> reported Reuters. </a> "On regulatory approval in India, RDIF (Russian Direct Investment Fund) shall supply to Dr Reddy's 100 million doses of the vaccine. The Sputnik V vaccine, which is based on well-studied human adenoviral vector platform with proven safety, is undergoing clinical trials for the coronavirus pandemic," said a statement from the fund. The development comes after the Russian government sought India’s help, earlier this month, in manufacturing the Sputnik V vaccine and also to conduct Phase III trials in India. According to the Russian Direct Investment Fund, the deliveries can begin in the late 2020. "The agreement between RDIF and Dr Reddy's reflects the growing awareness of countries and organisations to have a diversified anti-COVID vaccine portfolio to protect their populations," RDIF added. Sputnik V is under Phase III trials in Russia. Gamaleya Research Institute — a part of Russia’s Health Ministry — is testing the vaccine on over 40,000 people. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/india/news/brinton-pharma-which-recently-got-dcgi-approval-to-launch-covid-19-drug-favipiravir-in-india-gets-10-crore-in-debt-funding/articleshow/78145260.cms">Brinton Pharma, which recently got DCGI approval to launch COVID-19 drug Favipiravir in India, gets ₹10 crore in debt funding</a>

India’s Dr Reddy’s Lab to get 100 million doses of Russia’s COVID-19 vaccine after regulatory approval

Hyderabad, Feb Pharma major Dr. Reddy's Laboratories Ltd on Friday announced that it has initiated the process with the <keyword id="282629" type="COMPANY" weightage="20" keywordseo="Drugs-Controller">Drugs Controller</keyword> General of India (<keyword id="172241" type="COMPANY" weightage="20" keywordseo="DCGI">DCGI</keyword>) for Emergency Use Authorization (<keyword id="2503801" type="COMPANY" weightage="20" keywordseo="EUA">EUA</keyword>) of the well-studied human adenoviral vector-based platform vaccine candidate, <keyword id="9739267" type="PERSON" weightage="20" keywordseo="Sputnik-V">Sputnik V</keyword>. As part of the review process, Dr. Reddy's will present the safety profile of the phase 2 study, and interim data of the phase 3 study, which is expected to complete by February 21, the Hyderabad-based firm said. Dr. Reddy's partnered with the Russian Direct Investment Fund (<keyword id="18165" type="COMPANY" weightage="20" keywordseo="rdif">RDIF</keyword>) in September 2020 to conduct the clinical trials of the Sputnik V and for its distribution rights in India. The vaccine is currently undergoing the phase 3 clinical trial in India. Sputnik V has demonstrated an efficacy rate of 91.6 per cent in the interim analysis of the phase 3 clinical trial, which included data on 19,866 volunteers in Russia, who received both the first and second doses of the vaccine. Sputnik V maintained a consistent efficacy at 91.8 per cent even among the group of 2,144 volunteers over 60 years old. "The efficacy of Sputnik V was reported to be 91.6 per cent by the Lancet, which is an impressive development in the fight against Covid-19. The initiation of the EUA process will be a critical step forward for us in ensuring speedy access to the Sputnik V vaccine in India," said G.V. Prasad, Co-chairman and Managing Director, Dr. Reddy's Laboratories. Sputnik V developed by the Gamaleya National Research Institute of Epidemiology and Microbiology was registered by the Ministry of Health of Russia on August 11, 2020 and became the world's first registered vaccine against Covid-19 based on the human adenoviral vector platform. More than 250 clinical studies over two decades have proven the safety, efficacy, and lack of negative long-term effects of adenoviral vaccines. Sputnik V is one of only three vaccines in the world with an efficacy of 91.6 per cent and has most authorizations granted with 26 countries globally. The vaccine has already been administered to more than two million people worldwide. SEE ALSO: <a href="https://www.businessinsider.in/entertainment/news/pewdiepies-lyrics-targeting-cocomelon-and-jk-rowling-that-may-have-gotten-youtube-angry-enough-to-pull-the-video-down/articleshow/81102941.cms">PewDiePie's lyrics targeting CocoMelon and JK Rowling may have gotten YouTube angry enough to pull the video down</a> <a href="https://www.businessinsider.in/business/ecommerce/news/flipkart-gets-leaner-with-a-300-million-jabong-write-off-as-ceo-kalyan-krishnamurthy-lists-out-the-priorities-for-2021/articleshow/81105083.cms">Flipkart gets leaner with a $300 million Jabong write-off as CEO Kalyan Krishnamurthy lists out the priorities for 2021</a> <a href="https://www.businessinsider.in/stock-market/news/happiest-minds-is-leveraging-its-partnerships-with-big-players-like-google-microsoft-aws-salesforce/articleshow/81105035.cms">Happiest Minds is a smaller company that does the same thing as MindTree and L&amp;T Infotech — but clearly it is doing it a lot better</a> <a href="https://www.businessinsider.in/tech/news/india-may-require-twitter-facebook-and-others-to-remove-unlawful-content-within-36-hours/articleshow/81104740.cms">India may require Twitter, Facebook and others to remove unlawful content within 36 hours</a>

Dr.Reddy's gets authorisation to start rolling out Sputnik V COVID-19 vaccine in India

New Delhi, With the Drug Controller General of India (DCGI) approving <keyword id="95879" type="COMPANY" weightage="20" keywordseo="Serum-Institute-of-India">Serum Institute of India</keyword>'s 'Covishield' vaccine and <keyword id="149108" type="PERSON" weightage="20" keywordseo="Bharat-Biotech">Bharat Biotech</keyword>'s 'Covaxin' for emergency use, paving way for their roll-out and administration to millions, Russian <keyword id="9739267" type="PERSON" weightage="20" keywordseo="Sputnik-V">Sputnik V</keyword> vaccine makers have said that they are working with <keyword id="6409874" type="DOMAIN" weightage="20" keywordseo="astrazeneca">AstraZeneca</keyword> (AZ) to take the efficacy of AZ vaccine to over 90%. In a tweet, Sputnik V said: "As Indian regulator recommends for approval full-dose regimen of AstraZeneca's vaccine with efficacy of 62.1% based on phase 3 clinical data. Sputnik V is working on clinical trials with AZ to increase the efficacy of AZ vaccine to over 90%". AstraZeneca is currently working with the Russians on the combination of their vaccine's vector with that from Sputnik V (showing 91.4% efficacy as per Phase 3 final control point recorded last month), precisely to see if that could help boost its vaccine's efficacy to over 90% as well. While both vaccines use adenoviral vector technology, the AstraZeneca vaccine is based on a chimpanzee adenovirus (which is not the most popular technology among the vaccinated as recently conducted polls indicated that, given a choice, consumers prefer other technologies), the Sputnik V vaccine is based on a human adenovirus. Unlike AstraZeneca, which uses one and the same component for both inoculations, the Russian vaccine uses two different ones in two separate inoculations. Using the latter approach could prove more efficient in achieving a longer-lasting immune response. Covishield and Covaxin have to be administered in two doses and can be stored at 2-8 degrees Celsius. The Drugs Controller General of India has also granted permission to <keyword id="63358" type="DOMAIN" weightage="20" keywordseo="Cadila-Healthcare">Cadila healthcare</keyword> for phase 3 clinical trial in India. The vaccine will be first offered to one crore healthcare workers, along with two crore frontline and essential workers and 27 crore elderly, mostly above the age of 50 years with co-morbidities. India will produce about 300 million doses of the Russian Sputnik V coronavirus vaccine in 2021, Head of the <keyword id="1397612" type="COMPANY" weightage="20" keywordseo="Russian-Direct-Investment-Fund">Russian Direct Investment Fund</keyword> (RDIF), Kirill Dmitriev, said in an interview with Rossiya 24 TV channel last month. "In India, we have agreements with four large manufacturers. India will produce about 300 million doses or more of the vaccine for us next year," Russian news agency Tass quoted him as saying. In September 2020, Dr. Reddy's Laboratories and RDIF entered into a partnership to conduct clinical trials of the Sputnik V vaccine and the rights for distribution of the first 100 million doses in India. Dr. Reddys and RDIF announced in December that they have commenced adaptive Phase 2 and 3 clinical trials for Sputnik V vaccine in India for Covid-19 after receiving the necessary clearance from the <keyword id="241784" type="COMPANY" weightage="20" keywordseo="Central-Drugs-Laboratory">Central Drugs Laboratory</keyword>, Kasauli. On August 11, 2020, the Sputnik V vaccine developed by the Gamaleya National Research Institute of Epidemiology and Microbiology was registered by the Ministry of Health of Russia and became the world's first registered vaccine against Covid-19 based on the human adenoviral vector platform. SEE ALSO: <a href="https://www.businessinsider.in/stock-market/news/top-stocks-to-watch-beml-hcl-tech-infosys-tech-mahindra-tcs-ril-tata-motors-hero-moto-tvs-and-others/articleshow/80089765.cms">Top stocks to watch — BEML, HCL Tech, Infosys, Tech Mahindra, TCS, RIL, Tata Motors Hero Moto, TVS, and others</a> <a href="https://www.businessinsider.in/business/auto/news/checkout-upcoming-new-cars-in-year-2021/slidelist/80025993.cms">Upcoming new cars in India in 2021 of Maruti, Tata, MG, Audi</a> <a href="https://www.businessinsider.in/international/news/questions-arise-about-jack-ma-whereabouts-as-alibaba-faces-scrutiny-from-the-chinese-government/articleshow/80090457.cms">Where is Jack Ma? Questions arise about the billionaire’s whereabouts as Alibaba faces scrutiny from the Chinese government</a>

Russian vaccine makers are trying to push AstraZeneca COVID-19 vaccine's efficacy to beyond 90%

<ul><li>The vaccine that will have to be taken in two doses, will cost less than $10 (₹740) in international markets.</li><li>However, the vaccine will be available free of charge for Russian citizens. </li><li><keyword id="10325662" type="UNKNOWN" weightage="20" keywordseo="russias-sputnik-v-vaccine">Russia’s Sputnik V vaccine</keyword> has an efficacy of 95% after 42 days of the first dose. </li></ul>Russia’s Sputnik V vaccine has an efficacy of <a href="https://www.ndtv.com/world-news/coronavirus-russia-says-sputnik-v-covid-19-95-effective-news-agency-afp-2329561">95%</a> after 42 days of the first dose. The results were released by Russia's health ministry, the state-run Gamaleya research centre and the Russian Direct Investment Fund (RDIF). For the study, 22,000 volunteers had been vaccinated for the first dose and more than 19,000 volunteers with the first and second doses. The vaccine that will have to be taken in two doses, will cost less than $10 (₹740) in international markets. However, the vaccine will be available free of charge for Russian citizens. According to its current capacity, Sputnik V vaccine will be produced abroad for 500 million people per year, starting from 2021. “Sputnik V will be two or more times cheaper than mRNA vaccines with similar efficacy levels,” said the official statement. One of the international partners for the<a href="https://www.businessinsider.in/science/health/news/the-race-for-covid-19-vaccine-heres-how-moderna-pfizer-and-sputnik-v-vaccines-stack-up-against-each-other/articleshow/79263801.cms"> Sputnik V vaccine</a> is India, however requests for more than 1.2 billion doses of Sputnik V vaccine have come in from over 50 countries. “The Gamaleya Center has developed one of the most efficient vaccines against coronavirus in the world with an efficacy rate of more than 90% and a price that is two times lower than that of other vaccines with similar efficacy rate. We are ready to start deliveries of the Sputnik V vaccine to foreign markets thanks to partnerships with manufacturers in India, Brazil, South Korea, China and four other countries,” said Kirill Dmitriev, CEO, Russian Direct Investment Fund in a statement. The news of <keyword id="10325661" type="UNKNOWN" weightage="20" keywordseo="russias-vaccine">Russia’s vaccine</keyword> follows the positive news from Pfizer, Moderna and Oxford Astrazeneca — all of whom are progressing rapidly with their vaccine trials and are claiming success so far. <a href="https://www.businessinsider.in/science/health/news/the-oxford-covid-19-vaccine-will-only-cost-the-indian-government-3-per-dose-reveals-adar-poonawalla/articleshow/79371741.cms">Serum Institute of India</a> which will distribute the Oxford Astrazeneca vaccine had said that India will be a priority and will cost the Indian government $3 per dose. SEE ALSO: <a href="https://www.businessinsider.in/science/health/news/the-oxford-covid-19-vaccine-will-only-cost-the-indian-government-3-per-dose-reveals-adar-poonawalla/articleshow/79371741.cms">The Oxford COVID-19 vaccine will only cost the Indian government $3 per dose, reveals Adar Poonawalla</a>

Russia’s Sputnik V vaccine is 95% effective — each dose will cost less than $10 internationally but will be free for Russians

The <keyword id="682334" type="General" weightage="20" keywordseo="Drugs-Controller-General-of-India" source="Orion">Drugs Controller General of India</keyword> (DCGI) has granted permission for the conducting of the Phase III bridging trials of Sputnik Light on the Indian population. The Sputnik Light is a single-dose <keyword id="8904563" type="General" weightage="20" keywordseo="COVID-19-vaccine" source="Orion">Covid-19 vaccine</keyword> of the <keyword id="9340724" type="General" weightage="20" keywordseo="Russian-vaccine" source="Orion">Russian vaccine</keyword> Sputnik. The nod comes after a recent study published in the medical journal The Lancet said that Sputnik Light showed 78.6 to 83.7 per cent efficacy against Covid-19, significantly higher than most two-shot vaccines. The Subject Expert Committee of the Central Drugs Standard Control Organisation (CDSCO) in July had refused to grant emergency-use authorisation to Sputnik-Light, ruling out the need for the conduct of the <keyword id="9915130" type="General" weightage="20" keywordseo="phase-III-trial" source="Orion">phase III trial</keyword> of the Russian vaccine in the country. The committee had noted that Sputnik Light was the same as component-1 of <keyword id="9739267" type="General" weightage="20" keywordseo="Sputnik-V" source="Orion">Sputnik V</keyword> and its safety and immunogenicity data in the Indian population was already generated in a trial. The study was conducted on at least 40,000 elderly people in Argentina. Sputnik Light also reduced hospitalizations among the target population at 82.1-87.6 per cent, the study said. The Russian Direct Investment Fund (RDIF) last year partnered with Dr Reddy's Laboratories to conduct the phase III trials of Sputnik V vaccine in India. In April, Sputnik V received an emergency use authorisation in India. Reddy's administered the first dose of the vaccine in Hyderabad under a limited pilot on May 14. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/tech/news/ios-15-will-be-released-for-all-compatible-iphones-on-september-20/articleshow/86223330.cms">Everything you need to know about iOS 15: Release date, new features, supported devices</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/stock-market/news/analysts-recommend-buying-zee-entertainment-on-end-to-concerns-over-corporate-governance/articleshow/86222841.cms">Zee Entertainment good to buy as concerns over corporate governance will be put to bed after management change, say analysts</a>

DCGI permits to conduct the third phase trials of Sputnik V COVID-19 vaccine in India

Union Health Minister <keyword id="196226" type="PERSON" weightage="20" keywordseo="Harsh-Vardhan">Harsh Vardhan</keyword> clarified on Sunday that the government is yet to take a final decision on phase-3 trials of the Russian COVID-19 vaccine candidate Sputnik V. "This issue is still under consideration and no final decision on Sputnik V vaccine developed by Russia has been taken as yet," he stated while addressing his social media audience during his weekly programme 'Sunday Samvaad'. The clarification by the minister has come after a pharmaceutical giant, which partnered with Russia's sovereign wealth fund in September to conduct final trials and distribution of the Sputnik V, sought permission for the same from <keyword id="682334" type="COMPANY" weightage="20" keywordseo="Drugs-Controller-General-of-India">Drugs Controller General of India</keyword> (DCGI) on Friday. Hyderabad-based drugmaker Dr Reddy's Laboratories (DRL) had partnered the <keyword id="1397612" type="COMPANY" weightage="20" keywordseo="Russian-Direct-Investment-Fund">Russian Direct Investment Fund</keyword> (RDIF) last month to conduct final-stage human trials and distribution of Russia's Sputnik V Covid-19 vaccine in India. Two days ago, the DRL had applied to the DCGI for permission to conduct the phase-3 human clinical trials of Sputnik. Upon regulatory approval in India, RDIF will supply Dr Reddy's 100 million doses of the vaccine, the firm had said last month. The trials of Sputnik V are mired in controversy. The Russian government registered Sputnik V as a COVID-19 vaccine without conducting final clinical trials. Besides, the phase I and II of the trials involved merely 76 participants. The Indian scientists and medical experts are also of the opinion that the Indian government should conduct phase-2 trials of the vaccine to prove its safety and efficacy. Russia, had announced in August that it has developed the world's first <keyword id="1754604" type="PERSON" weightage="20" keywordseo="coronavirus">coronavirus</keyword> vaccine. However, the country had made the announcement before completion of phase-3 trials. A vaccine is deemed safe to be commercially available only after a larger efficacy trial which involves thousands of participants in the phase-3. However, the study of Sputnik trials published in The Lancet declared the vaccine as "Safe, well-tolerated, and does not cause serious adverse events in <keyword id="10049599" type="UNKNOWN" weightage="20" keywordseo="healthy-adult-volunteers">healthy adult volunteers</keyword>." As per the study, two small trials were conducted on two groups involving 38 healthy adults between the ages of 18 and 60, each. They were given a two-part immunisation. Each participant was given a dose of the first part of the vaccine, and then a booster with the second part, 21 days later. These volunteers were monitored over 42 days, and it was found that all of them developed antibodies against the virus within three weeks. After widespread criticism of conducting relatively small and early trials before registering Sputnik V as a COVID-19 vaccine, Russia said that a more rigorous phase-3 <keyword id="122283" type="PERSON" weightage="20" keywordseo="Clinical-trial">clinical trial</keyword> has been planned with the involvement of 40,000 volunteers "from different age and risk groups". SEE ALSO: <a href="https://www.businessinsider.in/science/health/news/latest-update-on-covid-19-vaccine-in-india/articleshow/78422652.cms" data-type="tilCustomLink">India COVID-19 vaccine updates — Zydus, Biotech enter clinical trials, Dr Reddy’s yet to apply for Sputnik V phase-III trials</a> <a href="https://www.businessinsider.in/stock-market/news/investors-must-brace-for-a-turbulent-october-in-the-stock-market-but-they-should-hold-on-for-a-strong-4th-quarter-finish-a-senior-wall-street-strategist-says/articleshow/78477243.cms" data-type="tilCustomLink">Investors must brace for a turbulent October in the stock market — but they should hold on for a strong 4th-quarter finish, a senior Wall Street strategist says</a>

Centre yet to decide on phase-3 trials of Russian COVID-19 vaccine Sputnik V, says Health Minister Harsh Vardhan

The <keyword id="95879" type="COMPANY" weightage="20" keywordseo="Serum-Institute-of-India">Serum Institute of India</keyword> (<keyword id="52604" type="COMPANY" weightage="20" keywordseo="SII">SII</keyword>) has applied to the Drug Controller General of India (<keyword id="172241" type="COMPANY" weightage="20" keywordseo="DCGI">DCGI</keyword>) seeking permission to manufacture COVID-19 vaccine <keyword id="9739267" type="PERSON" weightage="20" keywordseo="Sputnik-V">Sputnik V</keyword> in the country, sources said on Thursday. The Pune-based firm has also sought approval for test analysis and examination. Russia's Sputnik V vaccine is currently being manufactured in India by Dr Reddy's Laboratories. "The <keyword id="242973" type="COMPANY" weightage="20" keywordseo="Serum-Institute">Serum Institute</keyword> of India (SII) put up an application to the <keyword id="282629" type="COMPANY" weightage="20" keywordseo="Drugs-Controller">Drugs Controller</keyword> General of India (DCGI) on Wednesday seeking permission to manufacture the COVID-19 vaccine, Sputnik V, in India," a source said. The SII has already told the government that it will be able to manufacture and supply 10 crore Covishield doses in June, while it is also manufacturing the Novavax vaccine, the regulatory clearance for which is awaited from the United States. The vaccine was given emergency use authorisation (<keyword id="2503801" type="COMPANY" weightage="20" keywordseo="EUA">EUA</keyword>) by the DCGI in April. A consignment of 30 lakh doses of Sputnik V landed in Hyderabad on Tuesday. SEE ALSO: <a href="https://www.businessinsider.in/science/health/news/the-indian-government-is-doling-out-1500-crore-to-reserve-300-million-of-biological-es-covid-19-vaccine-doses/articleshow/83196362.cms">The Indian government is doling out ₹1500 crore to reserve 300 million of Biological-E’s COVID-19 vaccine doses</a> <a href="https://www.businessinsider.in/tech/news/huawei-announces-first-devices-with-harmonyos-set-to-take-on-apple-and-google-with-its-in-house-operating-system/articleshow/83195689.cms">Huawei announces first devices with HarmonyOS — set to take on Apple and Google with its in-house operating system</a> <a href="https://www.businessinsider.in/tech/mobile/news/oneplus-nord-ce-5g-mobile-phone-full-specifications-leaked-days-ahead-of-launch/articleshow/83195375.cms">OnePlus Nord CE 5G full specifications leaked days ahead of launch – heavily inspired by the original Nord</a> <a href="https://www.businessinsider.in/business/startups/news/top-five-fintech-ideas-that-are-drawing-the-most-amount-of-money/slidelist/83194276.cms">Five fintech ideas that are raking in the most amount of money</a>

Serum Institute of India seeks permission from DCGI to manufacture 'Sputnik V' COVID-19 vaccine in the country

An expert panel of India's central drug authority has recommended granting approval to Russian COVID-19 vaccine Sputnik V for emergency use in the country with certain conditions, sources said. The Subject Expert Committee (<keyword id="6362470" type="COMPANY" weightage="20" keywordseo="sec">SEC</keyword>) of the <keyword id="589469" type="COMPANY" weightage="20" keywordseo="Central-Drugs-Standard-Control-Organization">Central Drugs Standard Control Organization</keyword> (CDSCO) on Monday took up the application of Dr Reddy's Laboratories seeking emergency use authorisation for Sputnik V. The Drugs Controller General of India (<keyword id="172241" type="COMPANY" weightage="20" keywordseo="DCGI">DCGI</keyword>) will take a final call on the recommendation. If approved, it will be the third COVID-19 vaccine to be available in India. The vaccine would be imported from Russia for emergency use in the country, they said. In September last year, Dr Reddy's partnered with the <keyword id="1397612" type="COMPANY" weightage="20" keywordseo="Russian-Direct-Investment-Fund">Russian Direct Investment Fund</keyword> (RDIF) to conduct clinical trials of Sputnik V and for its distribution rights in India. The Drugs Controller General of India (DCGI) has already given the emergency use authorisation for two COVID-19 vaccines -- Covaxin of <keyword id="149108" type="PERSON" weightage="20" keywordseo="Bharat-Biotech">Bharat Biotech</keyword> and Covishield of Oxford-AstraZeneca, being manufactured by <keyword id="95879" type="COMPANY" weightage="20" keywordseo="Serum-Institute-of-India">Serum Institute of India</keyword> in Pune. Sputnik V has demonstrated an efficacy rate of 91.6 per cent in the interim analysis of phase 3 clinical trial, which included data on 19,866 volunteers in Russia. SEE ALSO: <a href="https://www.businessinsider.in/tech/news/aadhaar-pan-and-bank-account-numbers-leaked-in-upstox-data-breach/articleshow/82025949.cms">Discount broker Upstox suffers data breach – Aadhaar, PAN and bank account numbers leaked</a> <a href="https://www.businessinsider.in/science/environment/news/how-ash-from-st-vincents-volcano-is-covering-the-caribbeans-largest-island-nation/slidelist/82025420.cms">Devastating images show how ash from St Vincent’s volcano is covering the Caribbean's largest island nation</a> <a href="https://www.businessinsider.in/tech/mobile/news/lg-wing-gets-a-40000-price-cut-a-week-after-the-company-shuts-its-smartphone-business/articleshow/82027401.cms">LG Wing gets a ₹40,000 price cut a week after the company shuts its smartphone business</a>

You Searched For "sputnik v india" and got 10 results

India will produce 300 million doses of the Russian Sputnik V COVID-19 vaccine next year

Prabhjote Gill

India will receive the first batch of Sputnik V COVID-19 vaccine by May 1 — in time for the third phase of its vaccination drive

Prabhjote Gill

India’s Dr Reddy’s Lab to get 100 million doses of Russia’s COVID-19 vaccine after regulatory approval

BI India Bureau

Dr.Reddy's gets authorisation to start rolling out Sputnik V COVID-19 vaccine in India

IANS

Russian vaccine makers are trying to push AstraZeneca COVID-19 vaccine's efficacy to beyond 90%

IANS

Russia’s Sputnik V vaccine is 95% effective — each dose will cost less than $10 internationally but will be free for Russians

Sanchita Dash

DCGI permits to conduct the third phase trials of Sputnik V COVID-19 vaccine in India

IANS

Centre yet to decide on phase-3 trials of Russian COVID-19 vaccine Sputnik V, says Health Minister Harsh Vardhan

IANS

Serum Institute of India seeks permission from DCGI to manufacture 'Sputnik V' COVID-19 vaccine in the country

PTI

Russia’s Sputnik V COVID-19 vaccine recommended for emergency use in India

PTI

Popular Keywords

Buying Guides